A vial of Melanotan 2 (MT2) 10iu, manufactured by PUCA, was submitted for analytical testing. Both the submission and funding were conducted by PUCA (Manufacturer). The peptide was assessed by Janoshik Analytical, a third-party lab with expertise in verifying peptide identity and purity.
The measured content was 9.58 mg, slightly under the typical expected 10 mg fill for a 10iu vial, resulting in a 4.2% underdose. Purity was reported at an exceptional 99.811%, indicating very high chemical quality despite the slight variance in fill volume.
Detailed Report
Product Overview
- Manufacturer: PUCA
- Product Name: Melanotan 2 (MT2)
- Active Ingredient: Melanotan 2
- Labeled Concentration: 10 mg (typical for 10iu)
- Measured Concentration: 9.58 mg
- Purity: 99.811%
- Batch Number: 001
- Expiration Date: Not Provided
- Delivery Method: Peptide vial (10iu)
Sample Acquisition and Testing
- Task Number: #61629
- Testing Ordered: 20 March 2025
- Sample Received: 4 April 2025
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: PUCA (Manufacturer)
- Analysis Paid For By: PUCA (Manufacturer)
Testing Results
| Component/Test | Specification (Label Claim) | Measured Value | Accuracy | Variance |
|---|---|---|---|---|
| Melanotan 2 (MT2) | 10 mg | 9.58 mg | 95.8% | -4.2% |
| Purity | — | 99.811% | — | — |
Verification Details
- Verification URL: https://janoshik.com/tests/61629_UZVBAP7SB5PK
Evaluation of Manufacturer Testing
The PUCA MT2 vial demonstrated a measured fill of 9.58 mg with 99.811% purity. While the underdose is slight and within an arguably acceptable margin for peptide vials, it’s important for dosing accuracy and user trust.
Because the sample was submitted and funded by the manufacturer, the results represent an internal quality control effort. To build consumer confidence and eliminate bias, these types of results are ideally complemented by third-party or user-submitted tests.
Conclusion
PUCA’s Melanotan 2 MT2 10iu sample tested at 9.58 mg with 99.811% purity, reflecting strong quality standards and a minor variance from label expectations. The manufacturer’s proactive testing adds transparency, but consumers should still seek independent data for full assurance.
Disclaimer
This report is published for educational and harm reduction purposes. The findings reflect only a single manufacturer-funded batch. Third-party testing across multiple lots is encouraged to verify consistency and dosing accuracy in commercially distributed products.
